E CONF SERIES

International Conference on Educational Discoveries and Humanities
Hosted online from Moscow, Russia
Website: econfseries.com 16th May, 2025

DEFINITION OF AUTOIMMUNE HEPATITIS AND LABORATORY FEATURES

Qodirova Gulira'no Abduxapiz qizi
Assistant of Department Epidemiology and Infectious disease, Nursing work,
Ferghana Medical Institute of Public Health

Annotation

Autoimmune hepatitis is a chronic disorder characterized by continuing hepatocellular necrosis and inflammation, usually with fibrosis, which can progress to cirrhosis and liver failure. When fulfilling criteria of severity, this type of chronic hepatitis, when untreated, may have a 6-month mortality of as high as 40%. Based on contemporary estimates of the natural history of treated autoimmune hepatitis, the 10-year survival is 80–90%. The prominence of extrahepatic features of autoimmunity as well as seroimmunologic abnormalities in this disorder supports an autoimmune process in its pathogenesis; this concept is reflected in the labels lupoid, plasma cell, or autoimmune hepatitis. Autoantibodies and other typical features of autoimmunity, however, do not occur in all cases; among the broader categories of "idiopathic" or cryptogenic chronic hepatitis, many, perhaps the majority, are probably autoimmune in origin.

Keywords: autoimmune hepatitis, serum bilirubin, alkaline phosphatase, globulin, aminotransferase, hypergammaglobulinemia.

Laboratory features of autoimmune hepatitis are similar to those seen in chronic viral hepatitis. Liver biochemical tests are invariably abnormal but may not correlate with the clinical severity or histopathologic features in individual cases. Many patients with autoimmune hepatitis have normal serum bilirubin, alkaline phosphatase, and globulin levels with only minimal aminotransferase elevations. Serum AST and ALT levels are increased and fluctuate in the range of 100–1000 units. In severe cases, the serum bilirubin level is moderately elevated [51–171 µmol/L (3–10 mg/dL)]. Hypoalbuminemia occurs in patients with very active or advanced disease. Serum alkaline phosphatase levels may be moderately elevated or near normal. In a small proportion of patients, marked elevations of alkaline phosphatase activity

occur; in such patients, clinical and laboratory features overlap with those of primary biliary cirrhosis. The prothrombin time is often prolonged, particularly late in the disease or during active phases.

Hypergammaglobulinemia (>2.5 g/dL) is common in autoimmune hepatitis. Rheumatoid factor is common as well. As noted above, circulating autoantibodies are also prevalent.The most characteristic are ANAs in a homogeneous staining pattern. Smooth-muscle antibodies are less specific, seen just as frequently in chronic viral hepatitis. Because of the high levels of globulins achieved in the circulation of some patients with autoimmune hepatitis, occasionally the globulins may bind nonspecifically in solid-phase binding immunoassays for viral antibodies.This has been recognized most commonly in tests for antibodies to hepatitis C virus, as noted above. In fact, studies of autoantibodies in autoimmune hepatitis have led to the recognition of new categories of autoimmune hepatitis. Type I autoimmune hepatitis is the classic syndrome occurring in young women, associated with marked hyperglobulinemia, lupoid features, circulating ANAs, and HLA-DR3 or HLA-DR4. Also associated with type I autoimmune hepatitis are autoantibodies against actin as well as atypical perinuclear antineutrophilic cytoplasmic antibodies (pANCA).

Type II autoimmune hepatitis, often seen in children, more common in Mediterranean populations, and linked to HLA-DRB1 and HLA-DQB1 haplotypes, is associated not with ANA but with anti-LKM. Actually, anti-LKM represent a heterogeneous group of antibodies. In type II autoimmune hepatitis, the antibody is anti-LKM1, directed against cytochrome P450 2D6. This is the same anti-LKM seen in some patients with chronic hepatitis C. Anti-LKM2 is seen in drug-induced hepatitis, and anti-LKM3 is seen in patients with chronic hepatitis D. Another autoantibody observed in type II autoimmune hepatitis is directed against liver cytosol formiminotransferase cyclodeaminase (anti-liver cytosol 1). Another type of autoimmune hepatitis has been recognized, type III autoimmune hepatitis. These patients lack ANA and anti-LKM1 but have circulating antibodies to soluble liver antigen/liver pancreas antigen. Most of these patients are women and have clinical features similar to, perhaps more severe than, those of patients with type I autoimmune hepatitis. Whether type III autoimmune hepatitis actually represents a

distinct category or is part of the spectrum of type I autoimmune hepatitis remains controversial, and this subcategory has not been adopted by a consensus of international experts.

All in all, autoimmune hepatitis is a liver disease that happens when the body's immune system attacks the liver. This can cause swelling, irritation and damage to the liver. The exact cause of autoimmune hepatitis is unclear, but genetic and environmental factors appear to interact over time to trigger the disease.

Reference

1. Пулатова, Н. С., Йигиталиев, А. Б., & Абдурашидов, А. А. ЭПИДЕМИОЛОГИЯ РАКА ТЕЛА МАТКИ В ФЕРГАНСКОЙ ОБЛАСТИ. 1-SON, 1-JILD IYUL 2022 1-QISM, 29.
2. Эгамбердиев, Д. Э., Абдурашидов, А. А., & Эргашов, У. Ш. ПРОФИЛАКТИКА И МЕТОФИЛАКТИКА МОЧЕКАМЕННОЙ БОЛЕЗНИ.
3. Tohirbek To‘lqinjon o‘g, S. (2025, February). STRUCTURE AND FUNCTIONS OF THE URETHRAL SPHINCTER IN MEN. In Scientific Conference on Multidisciplinary Studies (pp. 165-171).
4. Хошимова, А. Ё. (2018). ВЛИЯНИЕ ЗАГРЯЗНЕНИЯ ОКРУЖАЮЩЕЙ СРЕДЫ НА ЗАБОЛЕВАЕМОСТЬ БРОНХИАЛЬНОЙ АСТМОЙ. Актуальные вопросы современной пульмонологии. Ma, 200.
5. Habibullayevna, A. G., & Shavkatjon o’g’li, Q. S. (2025, February). STRUCTURE AND INTRACELLULAR ACTIVITY OF THE DNA-CONTAINING HERPES SIMPLEX VIRUS. In International Educators Conference (pp. 126-132).
6. Ашуров, Д. Д. (2025, February). ВЫПАДЕНИЕ ВОЛОС (АЛОПЕЦИЯ) У ДЕТЕЙ. In International Conference on Modern Science and Scientific Studies (pp. 17-20).
7. Davlatovich, A. D. (2025). CLASSIFICATION OF TATTOOS AND TATTOO REMOVAL. Web of Medicine: Journal of Medicine, Practice and Nursing, 3(2), 431-434.

8. Ашуров, Д. Д. (2025, February). ИНВАЗИВНЫЕ МЕТОДЫ ЛЕЧЕНИЯ ВИТИЛИГО. In International Conference on Modern Science and Scientific Studies (pp. 304-307).
9. Мухидинова, Ш. Б. (2016). ЭПИДЕМИОЛОГИЧЕСКИЕ ОСОБЕННОСТИ ТУБЕРКУЛЕЗА. Актуальные вопросы современной пульмонологии. Ма, 144.
10. Каландарова, М. Х. (2024). ФИЗИОЛОГИЧЕСКИЕ ОСНОВЫ РАЦИОНАЛЬНОГО ПИТАНИЯ. Eurasian Journal of Medical and Natural Sciences, 4(1-1), 235-240.
11. Ходжиакбаровна, КМ (2025, февраль). РОЛЬ ЛЕЧЕБНОЙ ФИЗИЧЕСКОЙ КУЛЬТУРЫ В ВОССТАНОВЛЕНИИ COVID-19. В материалах Международной конференции по современной науке и научным исследованиям (стр. 3-7).
12. Ходжиакбаровна, КМ (2025, февраль). НЕГАТИВНЫЕ ПОСЛЕДСТВИЯ ГЕЛЬМИНТОЗОВ И ПРОФИЛАКТИЧЕСКИЕ МЕРЫ В ЛЕЧЕНИИ. В сборнике материалов Международной конференции по современной науке и научным исследованиям (стр. 323-326).
13. Khodzhiakbarovna, K. M. (2023). IMPORTANCE OF FOLK MEDICINE IN THE TREATMENT OF DISEASES. JOURNAL OF MEDICINE AND PHARMACY, 7(1), 1-5.
14. Rapikov, I. (2023). Formation of savings and entrepreneurship on the basis of labor education according to age characteristics in primary school students. Procedia of Engineering and Medical Sciences, 8(12), 80-83.
15. Tohirbek To'lqinjon o'g, S. (2024). Successful testicular sperm extraction in an infertile man with non-obstructive azoospermia and hypergonadotropic hypogonadism presenting with bilateral atrophic testis: a case report. Miasto Przyszłości, 48, 186-188.
16. Шухратжон у'г'ли, СЭ (2025, январь). РАСПРОСТРАНЕННОСТЬ И ЭТИОЛОГИЯ ГИПОСПАДИИ. На Международной конференции по междисциплинарным наукам и образовательной практике (стр. 99-104).

17. Qodirova, G. A., & Ibrohimova, M. (2025, February). TREATMENT METHODS AND COMPLICATIONS OF SCARLET FEVER. In International Educators Conference (pp. 175-181).
18. Каримова, М. М. (2019). ЙОД БИЛАН ТАЪМИНЛАНГАНЛИК ВА ЙОД ТАНҚИСЛИГИ ШАРОИТИДА ТУГУНЛИ БУҚОҚНИНГ ШАКЛЛАРИ КЎРИНИШЛАРИ БЎЙИЧА БАЖАРИЛГАН ЖАРРОҲЛИК ОПЕРАЦИЯЛАР СОНИ ВА ҲАЖМИНИНГ ДИНАМИК ЎЗГАРИШЛАРИ. Журнал. Доктор Ахборотномаси. Самарканд, (1), 57-61.
19. Каримова, М. М. (2020). ИССЛЕДОВАНИЕ ВЛИЯНИЯ БИОКОМПЛЕКСОВ НА ПЕРЕКИСНОЕ ОКИСЛЕНИЕ ЛИПИДОВ ИЗОЛИРОВАННЫХ ГЕПАТОЦИТОВ. Новый день в медицине, (1), 498-500.
20. Каримова, М. М. (2020). ВЛИЯНИЕ ПАНДЕМИИ НОВОЙ КОРОНАВИРУСНОЙ ИНФЕКЦИИ НА ДЕЯТЕЛЬНОСТЬ ТАМОЖЕННЫХ ОРГАНОВ. In Взаимодействие таможенных органов с иными участниками таможенных отношений: особенности и перспективы развития (pp. 136-140).
21. Шамансурова, З. М., & Каримова, М. М. ИЗУЧЕНИЕ ВЛИЯНИЯ ИНФЕКЦИИ COVID-19 НА СОСТОЯНИЕ ТКАНИ ЩИТОВИДНОЙ ЖЕЛЕЗЫ.
22. Каримова, М. М., Мухамадсодиқов, М. М., & Абдулазихожиева, Р. Б. (2022). Қалқонсимон Без Саратонини Замонавий Ташхислаш, Даволаш Ва Текширув Усулларини Баҳолаш. AMALIY VA TIBBIYOT FANLARI ILMIY JURNALI, 1(6), 84-95.
23. Masrurjon o‘g‘li, M. M. (2024, May). HUMAN GROWTH HORMONE. In Proceedings of Scientific Conference on Multidisciplinary Studies (Vol. 3, No. 5, pp. 117-125).
24. Masrurjon o‘g‘li, M. M. (2024). COMMON THYROID DISEAGES, CAUSES AND ITS TREATMENT METHODS. Miasto Przyszłości, 48, 223-232.